A technology platform for identifying, measuring, and modulating SIRT4 lipoamidase activity in cellular metabolism

This technology identifies SIRT4 as an enzyme that removes lipoamide groups from mitochondrial proteins, regulating cellular metabolism, and provides methods to measure, modulate, and screen for compounds affecting SIRT4 activity for potential metabolic disease therapies.

Background

Mitochondrial metabolism is central to cellular energy production, with the pyruvate dehydrogenase complex (PDHC) serving as a critical gateway between glycolysis and the tricarboxylic acid (TCA) cycle. Proper regulation of PDHC activity is essential for maintaining metabolic homeostasis, and dysregulation is implicated in a range of diseases, including metabolic disorders, cancer, and neurodegeneration. Sirtuins, a family of NAD-dependent enzymes, have emerged as important regulators of mitochondrial function, influencing processes such as stress response, aging, and metabolic adaptation. However, the specific mechanisms by which individual sirtuins, particularly SIRT4, modulate mitochondrial enzymes and metabolic flux have remained poorly understood, highlighting a need for technologies that can dissect and manipulate these regulatory pathways.

Current approaches to studying and modulating mitochondrial metabolism face several limitations. Traditional assays for PDHC activity and mitochondrial function often lack specificity, sensitivity, or throughput, making it difficult to pinpoint regulatory nodes or identify subtle post-translational modifications that impact enzyme activity. Furthermore, the lack of robust, target-specific assays hampers the discovery of small molecules or biological agents that can selectively modulate key regulators like SIRT4. Existing methods also struggle to directly link changes in protein modification states—such as lipoylation on PDHC components—to functional metabolic outcomes, limiting their utility in both basic research and therapeutic development. These challenges underscore the need for more precise, high-throughput, and mechanistically informative tools to interrogate and manipulate mitochondrial metabolic regulation.

Technology

This technology centers on the identification and application of Sirtuin 4 (SIRT4) as a cellular lipoamidase that regulates mitochondrial metabolism by hydrolyzing lipoamide cofactors from the dihydrolipoyllysine acetyltransferase (DLAT) component of the pyruvate dehydrogenase complex (PDHC). The solution provides a suite of methods and tools—including SIRT4 polypeptides, engineered cell lines, and mass spectrometry-based assays—to screen for and characterize modulators of SIRT4 lipoamidase activity. Using these approaches, researchers can measure the extent of DLAT lipoylation, assess PDHC activity, and evaluate the impact of candidate agents (such as small molecules, nucleic acids, or antibodies) on mitochondrial acetyl-CoA production and overall cellular metabolism. The technology also identifies specific DLAT lysine residues (K259 and K132) as biomarkers for SIRT4 activity, enabling precise functional readouts in both high-throughput and targeted experimental settings.

What differentiates this technology is its elucidation of SIRT4’s unique enzymatic function—specifically, its ability to remove lipoyl and biotinyl modifications with high specificity and efficiency, a role not previously attributed to any other sirtuin. Unlike related enzymes such as SIRT3 and SIRT5, SIRT4’s activity directly modulates a critical metabolic node by controlling PDHC function, thereby influencing acetyl-CoA levels and downstream metabolic pathways. The comprehensive experimental framework, including recombinant protein systems, engineered cell models, and advanced proteomic assays, allows for robust screening and mechanistic studies of SIRT4 modulators. This positions the technology as a powerful platform for both basic research and therapeutic development, particularly in the context of metabolic disorders where fine-tuning mitochondrial function is of clinical interest.

Benefits

  • Precise regulation of mitochondrial metabolism through modulation of pyruvate dehydrogenase complex (PDHC) activity
  • Identification and quantification of specific biomarkers (DLAT lipoyl-K259 and K132) for monitoring SIRT4 lipoamidase activity
  • Robust assay platforms (LC-MS/MS, SRM-MS, functional PDHC assays) for screening and measuring SIRT4 activity and its modulators
  • Capability to discover and develop therapeutic agents that modulate SIRT4, potentially treating metabolic disorders by enhancing acetyl-CoA production
  • Use of engineered cell lines and recombinant proteins to facilitate high-throughput screening and mechanistic studies
  • Specific targeting of lipoyl and biotinyl modifications on mitochondrial enzymes, enabling selective metabolic control
  • Potential applications in understanding and managing diseases linked to mitochondrial dysfunction, such as cancer, diabetes, and cardiovascular conditions

Applications

  • Metabolic disorder drug screening
  • High-throughput SIRT4 inhibitor discovery
  • Biomarker-based metabolic diagnostics
  • Cell-based mitochondrial function assays

Additional info

Sirtuin 4 (SIRT4) functions as a mitochondrial lipoamidase, hydrolyzing lipoamide cofactors from the dihydrolipoyllysine acetyltransferase (DLAT) component of the pyruvate dehydrogenase complex (PDHC). By targeting lipoyl-K259 and K132 residues, SIRT4 suppresses PDHC activity and acetyl-CoA production. This technology provides screening methods for SIRT4 modulators and mass spectrometry-based assays (LC-MS/MS, SRM) to quantify DLAT lipoylation for treating metabolic, cardiovascular, and oncological disorders.